BRPI0716171A2 - composto, composiÇço farmacÊutica e uso de um composto. - Google Patents
composto, composiÇço farmacÊutica e uso de um composto.Info
- Publication number
- BRPI0716171A2 BRPI0716171A2 BRPI0716171-9A2A BRPI0716171A BRPI0716171A2 BR PI0716171 A2 BRPI0716171 A2 BR PI0716171A2 BR PI0716171 A BRPI0716171 A BR PI0716171A BR PI0716171 A2 BRPI0716171 A2 BR PI0716171A2
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- pharmaceutical composition
- pharmaceutical
- composition
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IBPCT/IB06/053147 | 2006-09-07 | ||
IB2006053147 | 2006-09-07 | ||
PCT/IB2007/053594 WO2008029371A1 (en) | 2006-09-07 | 2007-09-06 | Pyridin-4-yl derivatives as immunomodulating agents |
Publications (4)
Publication Number | Publication Date |
---|---|
BRPI0716171A2 true BRPI0716171A2 (pt) | 2013-09-17 |
BRPI0716171A8 BRPI0716171A8 (pt) | 2017-12-26 |
BRPI0716171B1 BRPI0716171B1 (pt) | 2021-05-11 |
BRPI0716171B8 BRPI0716171B8 (pt) | 2021-05-25 |
Family
ID=38983600
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0716171A BRPI0716171B8 (pt) | 2006-09-07 | 2007-09-06 | composto, composição farmacêutica e uso de um composto |
Country Status (27)
Country | Link |
---|---|
US (1) | US8580824B2 (pt) |
EP (1) | EP2069336B1 (pt) |
JP (1) | JP5253401B2 (pt) |
KR (1) | KR101470659B1 (pt) |
CN (1) | CN101511827B (pt) |
AR (1) | AR062683A1 (pt) |
AU (1) | AU2007292993B2 (pt) |
BR (1) | BRPI0716171B8 (pt) |
CA (1) | CA2661105C (pt) |
CL (1) | CL2007002593A1 (pt) |
CY (1) | CY1113727T1 (pt) |
DK (1) | DK2069336T3 (pt) |
ES (1) | ES2400533T3 (pt) |
HK (1) | HK1133654A1 (pt) |
HR (1) | HRP20130181T1 (pt) |
IL (1) | IL197393A (pt) |
MA (1) | MA30718B1 (pt) |
MX (1) | MX2009002233A (pt) |
MY (1) | MY149853A (pt) |
NO (1) | NO342156B1 (pt) |
NZ (1) | NZ576060A (pt) |
PL (1) | PL2069336T3 (pt) |
PT (1) | PT2069336E (pt) |
RU (1) | RU2447071C2 (pt) |
SI (1) | SI2069336T1 (pt) |
TW (1) | TWI392671B (pt) |
WO (1) | WO2008029371A1 (pt) |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI2069335T1 (sl) * | 2006-09-08 | 2013-04-30 | Actelion Pharmaceuticals Ltd. | Derivati piridin-3-ila kot imunomodulacijska sredstva |
CA2662673A1 (en) * | 2006-09-21 | 2008-03-27 | Martin Bolli | Phenyl derivatives and their use as immunomodulators |
EP2109364A4 (en) | 2006-12-15 | 2010-04-14 | Abbott Lab | NOVEL OXADIAZONE COMPOUNDS |
JO2701B1 (en) | 2006-12-21 | 2013-03-03 | جلاكسو جروب ليميتد | Vehicles |
BRPI0808789A2 (pt) * | 2007-03-16 | 2014-08-12 | Actelion Pharmaceuticals Ltd | Compostos e composição farmacêutica de derivados aminopiridina e uso destes |
NZ583957A (en) * | 2007-08-17 | 2011-09-30 | Actelion Pharmaceuticals Ltd | Pyridine derivatives as s1p1/edg1 receptor modulators |
NZ585775A (en) * | 2007-11-01 | 2011-12-22 | Actelion Pharmaceuticals Ltd | Novel pyrimidine derivatives |
ES2389042T3 (es) * | 2008-03-06 | 2012-10-22 | Actelion Pharmaceuticals Ltd. | Compuestos de piridina |
EP2262800A1 (en) * | 2008-03-06 | 2010-12-22 | Actelion Pharmaceuticals Ltd. | Novel pyrimidine-pyridine derivatives |
MX2010009645A (es) * | 2008-03-07 | 2010-09-28 | Actelion Pharmaceuticals Ltd | Derivados novedosos de aminometil benceno. |
CA2715437C (en) * | 2008-03-07 | 2016-05-24 | Actelion Pharmaceuticals Ltd | Pyridin-2-yl derivatives as immunomodulating agents |
US8785484B2 (en) | 2008-03-17 | 2014-07-22 | Actelion Pharmaceuticals Ltd | Dosing regimen for a selective S1P1 receptor agonist |
TWI490214B (zh) * | 2008-05-30 | 2015-07-01 | 艾德克 上野股份有限公司 | 苯或噻吩衍生物及該等作為vap-1抑制劑之用途 |
KR20190004843A (ko) | 2008-07-23 | 2019-01-14 | 아레나 파마슈티칼스, 인크. | 자가면역성 및 염증성의 장애의 치료에 유용한 치환된 1,2,3,4-테트라히드로시클로펜타[b]인돌-3-일)아세트산 유도체 |
US8415484B2 (en) | 2008-08-27 | 2013-04-09 | Arena Pharmaceuticals, Inc. | Substituted tricyclic acid derivatives as S1P1 receptor agonists useful in the treatment of autoimmune and inflammatory disorders |
JP2012515788A (ja) | 2009-01-23 | 2012-07-12 | ブリストル−マイヤーズ スクイブ カンパニー | 自己免疫疾患および炎症性疾患の処置における、s1pアゴニストとしての置換オキサジアゾール誘導体 |
JP2012515787A (ja) | 2009-01-23 | 2012-07-12 | ブリストル−マイヤーズ スクイブ カンパニー | 自己免疫疾患および炎症性疾患の処置におけるs1pアゴニストとしての置換オキサジアゾール誘導体 |
WO2010085584A1 (en) | 2009-01-23 | 2010-07-29 | Bristol-Myers Squibb Company | Pyrazole-i, 2, 4 -oxad iazole derivatives as s.phing0sine-1-ph0sphate agonists |
ES2517265T3 (es) * | 2009-03-03 | 2014-11-03 | Merck Serono S.A. | Derivados de oxadiazol piridina |
CN102395564A (zh) * | 2009-04-17 | 2012-03-28 | 石原产业株式会社 | 2-卤代-6-取代-4-三氟甲基吡啶的生产方法 |
DE102009002514A1 (de) * | 2009-04-21 | 2010-10-28 | Evonik Degussa Gmbh | Verfahren zur Herstellung von substituierten 1,4-Chinonmethiden |
SG178042A1 (en) * | 2009-07-16 | 2012-03-29 | Actelion Pharmaceuticals Ltd | Pyridin-4-yl derivatives |
US8399451B2 (en) | 2009-08-07 | 2013-03-19 | Bristol-Myers Squibb Company | Heterocyclic compounds |
EP4148045A1 (en) | 2010-01-27 | 2023-03-15 | Arena Pharmaceuticals, Inc. | Intermediate compounds for the preparation of (r)-2-(7-(4-cyclopentyl-3- (trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b] indol-3-yl)acetic acid and salts thereof |
CA2789480A1 (en) | 2010-03-03 | 2011-09-09 | Arena Pharmaceuticals, Inc. | Processes for the preparation of s1p1 receptor modulators and crystalline forms thereof |
EP2560969B1 (en) | 2010-04-23 | 2015-08-12 | Bristol-Myers Squibb Company | 4-(5-isoxazolyl or 5-pyrrazolyl-1,2,4-oxadiazol-3-yl)-mandelic acid amides as sphingosin-1-phosphate 1 receptor agonists |
ES2539256T3 (es) | 2010-07-20 | 2015-06-29 | Bristol-Myers Squibb Company | Compuestos de 3-fenil-1,2,4-oxadiazol sustituidos |
ES2548258T3 (es) | 2010-09-24 | 2015-10-15 | Bristol-Myers Squibb Company | Compuestos de oxadiazol sustituidos y su uso como agonistas de S1P1 |
EP2665720B1 (en) * | 2011-01-19 | 2015-06-10 | Actelion Pharmaceuticals Ltd. | 2-methoxy-pyridin-4-yl derivatives |
CA2895172C (en) | 2012-08-17 | 2020-08-18 | Actelion Pharmaceuticals Ltd | Process for the preparation of|(2z,5z)-5-(3-chloro-4-((r)-2,3-dihydroxypropoxy)benzylidene)-2-(propylimino)-3-|(o-tolyl)thiazolidin-4-one and intermediate used in said process |
JP6387361B2 (ja) * | 2013-03-15 | 2018-09-05 | イドーシア ファーマシューティカルズ リミテッドIdorsia Pharmaceuticals Ltd | ピリジン−4−イル誘導体 |
MX2021011472A (es) | 2015-01-06 | 2022-08-17 | Arena Pharm Inc | Metodos de condiciones de tratamiento relacionadas con el receptor s1p1. |
CA2981130C (en) | 2015-05-20 | 2021-06-01 | Cyrille Lescop | Crystalline form of the compound (s)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1,2-diol |
US10111841B2 (en) | 2015-06-19 | 2018-10-30 | University Of South Florida | Stabilization of alcohol intoxication-induced cardiovascular instability |
PL3310760T3 (pl) | 2015-06-22 | 2023-03-06 | Arena Pharmaceuticals, Inc. | Krystaliczna sól L-argininy kwasu (R)-2-(7-(4-cyklopentylo-3-(trifluorometylo)benzyloksy)- 1,2,3,4-tetrahydrocyklo-penta[b]indol-3-ilo)octowego do zastosowania w zaburzeniach związanych z receptorem S1P1 |
WO2017004609A1 (en) * | 2015-07-02 | 2017-01-05 | Exelixis, Inc. | Thiadiazole modulators of s1p and methods of making and using |
WO2017004608A1 (en) * | 2015-07-02 | 2017-01-05 | Exelixis, Inc. | Oxadiazole modulators of s1p methods of making and using |
WO2017004610A1 (en) * | 2015-07-02 | 2017-01-05 | Exelixis, Inc. | Tercyclic s1p3-sparing, s1p1 receptor agonists |
CN110545848A (zh) | 2017-02-16 | 2019-12-06 | 艾尼纳制药公司 | 用于治疗具有肠外表现的炎症性肠病的化合物和方法 |
CN110520124A (zh) | 2017-02-16 | 2019-11-29 | 艾尼纳制药公司 | 用于治疗原发性胆汁性胆管炎的化合物和方法 |
CN107311994A (zh) * | 2017-08-14 | 2017-11-03 | 淄博职业学院 | 一种s1p‑1受体激动剂药物分子的新型合成方法 |
CA3079833A1 (en) | 2017-11-01 | 2019-05-09 | Bristol-Myers Squibb Company | Bridged bicyclic compounds as farnesoid x receptor modulators |
CN109956912B (zh) * | 2017-12-26 | 2021-10-22 | 中国医学科学院药物研究所 | 含二苯基噁二唑的羧酸类化合物、其制备方法及医药用途 |
WO2020051378A1 (en) | 2018-09-06 | 2020-03-12 | Arena Pharmaceuticals, Inc. | Compounds useful in the treatment of autoimmune and inflammatory disorders |
Family Cites Families (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL31990A (en) | 1968-04-26 | 1974-05-16 | Chinoin Gyogyszer Es Vegyeszet | Pyridyl 1,2,4-oxadiazole derivatives,process for the preparation thereof and pharmaceutical compositions containing same |
WO1991015583A1 (en) | 1990-04-05 | 1991-10-17 | The American National Red Cross | A protein family related to immediate-early protein expressed by human endothelial cells during differentiation |
AU653957B2 (en) | 1990-09-20 | 1994-10-20 | Merrell Dow Pharmaceuticals Inc. | 1-aryl-3-pyridinyl-2-propene-1-ones |
DE4429465A1 (de) | 1994-08-19 | 1996-02-22 | Bayer Ag | Verfahren zur Herstellung von 2-Halogenpyridinaldehyden und neue 2-Halogenpyridinaldehyde |
EP1070080A4 (en) | 1998-03-09 | 2004-12-29 | Smithkline Beecham Corp | HUMAN EDG-1c POLYNUCLEOTIDES AND POLYPEPTIDES AND THEIR APPLICATIONS |
DE19904389A1 (de) | 1999-02-04 | 2000-08-10 | Bayer Ag | Verwendung von substituierten Isoxazolcarbonsäuren und Derivate und neue Stoffe |
SK2512002A3 (en) | 1999-08-19 | 2002-07-02 | Nps Pharma Inc | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
EP1679313A3 (en) | 2001-02-21 | 2006-08-16 | Nps Pharmaceuticals, Inc. | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
WO2003062248A2 (en) | 2002-01-18 | 2003-07-31 | Merck & Co., Inc. | N-(benzyl)aminoalkylcarboxylates, phosphinates, phosphonates and tetrazoles as edg receptor agonists |
EP1470137B1 (en) | 2002-01-18 | 2009-09-02 | Merck & Co., Inc. | Edg receptor agonists |
US20040058894A1 (en) | 2002-01-18 | 2004-03-25 | Doherty George A. | Selective S1P1/Edg1 receptor agonists |
CA2488117A1 (en) | 2002-06-17 | 2003-12-24 | Merck & Co., Inc. | 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)azetidine-3-carboxylates and 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)pyrrolidine-3-carboxylates as edg receptor agonists |
DE10237883A1 (de) * | 2002-08-19 | 2004-03-04 | Merckle Gmbh Chem.-Pharm. Fabrik | Substituierte Isoxazolderivate und ihre Verwendung in der Pharmazie |
AU2003279915A1 (en) | 2002-10-15 | 2004-05-04 | Merck And Co., Inc. | Process for making azetidine-3-carboxylic acid |
US20050004186A1 (en) | 2002-12-20 | 2005-01-06 | Pfizer Inc | MEK inhibiting compounds |
WO2004103279A2 (en) | 2003-05-15 | 2004-12-02 | Merck & Co., Inc. | 3-(2-amino-1-azacyclyl)-5-aryl-1,2,4-oxadiazoles as s1p receptor agonists |
TW200505416A (en) | 2003-08-12 | 2005-02-16 | Mitsubishi Pharma Corp | Bi-aryl compound having immunosuppressive activity |
RU2390519C2 (ru) * | 2003-08-29 | 2010-05-27 | Оно Фармасьютикал Ко., Лтд. | Соединение, способное к связыванию с рецептором s1p, и его фармацевтическое применение |
WO2005032465A2 (en) | 2003-10-01 | 2005-04-14 | Merck & Co., Inc. | 3,5-aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as s1p receptor agonists |
US7605171B2 (en) | 2003-12-17 | 2009-10-20 | Merck & Co., Inc. | (3,4-disubstituted)propanoic carboxylates as S1P (Edg) receptor agonists |
WO2005115382A1 (en) | 2004-05-29 | 2005-12-08 | 7Tm Pharma A/S | Crth2 receptor ligands for medicinal uses |
WO2006010379A1 (en) | 2004-07-29 | 2006-02-02 | Actelion Pharmaceuticals Ltd. | Novel thiophene derivatives as immunosuppressive agents |
EP1804793A4 (en) | 2004-10-22 | 2010-03-31 | Merck Sharp & Dohme | 2- (ARYL) AZACYCLYLMETHYL-CARBOXYLATE, SULPHONATE, PHOSPHONATE, PHOSPHINATE AND HETEROCYCLES AS S1P RECEPTOR AGONISTS |
EP2371811B1 (en) | 2004-12-13 | 2014-10-08 | Ono Pharmaceutical Co., Ltd. | Azetidinecarboxylic acid derivative and medicinal use thereof |
DE602006003642D1 (en) | 2005-03-23 | 2008-12-24 | Actelion Pharmaceuticals Ltd | Neue thiophen-derivate als sphingosin-1-phosphat-1-rezeptorantagonisten |
MX2007011670A (es) * | 2005-03-23 | 2007-11-15 | Actelion Pharmaceuticals Ltd | Derivados de benzo(c) tiofeno hidrogenados como inmunomoduladores. |
KR20080002850A (ko) | 2005-03-23 | 2008-01-04 | 액테리온 파마슈티칼 리미티드 | 신규한 티오펜 유도체 |
MX2007012393A (es) | 2005-04-05 | 2008-02-22 | Pharmacopeia Inc | Derivados de purina e imidazopiridina para la inmunosupresion. |
RU2382781C2 (ru) | 2005-04-22 | 2010-02-27 | Дайити Санкио Компани, Лимитед | Гетероциклическое соединение |
KR20080000622A (ko) | 2005-04-26 | 2008-01-02 | 뉴로서치 에이/에스 | 신규한 옥사디아졸 유도체 및 이의 의학적 용도 |
CA2610310A1 (en) | 2005-06-08 | 2006-12-14 | Novartis Ag | Polycyclic oxadiazoles or isoxazoles and their use as s1p receptor ligands |
WO2006135694A2 (en) | 2005-06-10 | 2006-12-21 | Acadia Pharmaceuticals Inc. | Uii-modulating compounds and their use |
WO2006137019A1 (en) | 2005-06-24 | 2006-12-28 | Actelion Pharmaceuticals Ltd | Novel thiophene derivatives |
JP2008546836A (ja) | 2005-06-28 | 2008-12-25 | アストラゼネカ アクチボラグ | 新規な用途 |
AR057894A1 (es) | 2005-11-23 | 2007-12-26 | Actelion Pharmaceuticals Ltd | Derivados de tiofeno |
TWI404706B (zh) | 2006-01-11 | 2013-08-11 | Actelion Pharmaceuticals Ltd | 新穎噻吩衍生物 |
WO2007086001A2 (en) | 2006-01-24 | 2007-08-02 | Actelion Pharmaceuticals Ltd | Novel pyridine derivatives |
GB0601744D0 (en) | 2006-01-27 | 2006-03-08 | Novartis Ag | Organic compounds |
RU2008137553A (ru) | 2006-02-21 | 2010-03-27 | Юниверсити Оф Вирджиния Пэтент Фаундейшн (Us) | Фенил-циклоалкильные соединения, содержащие гетероциклические структуры |
EP2021338A1 (en) | 2006-05-09 | 2009-02-11 | Pfizer Products Inc. | Cycloalkylamino acid derivatives and pharmaceutical compositions thereof |
AR061841A1 (es) | 2006-09-07 | 2008-09-24 | Actelion Pharmaceuticals Ltd | Derivados de tiofen-oxadiazoles, agonistas del receptor s1p1/edg1, composiciones farmaceuticas que los contienen y usos como agentes inmunomoduladores. |
SI2069335T1 (sl) | 2006-09-08 | 2013-04-30 | Actelion Pharmaceuticals Ltd. | Derivati piridin-3-ila kot imunomodulacijska sredstva |
CA2662673A1 (en) | 2006-09-21 | 2008-03-27 | Martin Bolli | Phenyl derivatives and their use as immunomodulators |
KR20090057070A (ko) | 2006-09-29 | 2009-06-03 | 노파르티스 아게 | 소염성 및 면역억제성을 갖는 옥사디아졸 유도체 |
JP2008120794A (ja) | 2006-10-16 | 2008-05-29 | Daiichi Sankyo Co Ltd | ヘテロ環化合物を含有する医薬組成物 |
US20080138955A1 (en) * | 2006-12-12 | 2008-06-12 | Zhiyuan Ye | Formation of epitaxial layer containing silicon |
EP2109364A4 (en) | 2006-12-15 | 2010-04-14 | Abbott Lab | NOVEL OXADIAZONE COMPOUNDS |
WO2008091967A1 (en) | 2007-01-26 | 2008-07-31 | Smithkline Beecham Corporation | Chemical compounds |
BRPI0808789A2 (pt) | 2007-03-16 | 2014-08-12 | Actelion Pharmaceuticals Ltd | Compostos e composição farmacêutica de derivados aminopiridina e uso destes |
NZ583957A (en) | 2007-08-17 | 2011-09-30 | Actelion Pharmaceuticals Ltd | Pyridine derivatives as s1p1/edg1 receptor modulators |
NZ585775A (en) | 2007-11-01 | 2011-12-22 | Actelion Pharmaceuticals Ltd | Novel pyrimidine derivatives |
AU2008334297A1 (en) | 2007-12-10 | 2009-06-18 | Actelion Pharmaceuticals Ltd | Thiophene derivatives as agonists of S1P1/EDG1 |
EP2262800A1 (en) | 2008-03-06 | 2010-12-22 | Actelion Pharmaceuticals Ltd. | Novel pyrimidine-pyridine derivatives |
ES2389042T3 (es) | 2008-03-06 | 2012-10-22 | Actelion Pharmaceuticals Ltd. | Compuestos de piridina |
MX2010009645A (es) | 2008-03-07 | 2010-09-28 | Actelion Pharmaceuticals Ltd | Derivados novedosos de aminometil benceno. |
CA2715437C (en) | 2008-03-07 | 2016-05-24 | Actelion Pharmaceuticals Ltd | Pyridin-2-yl derivatives as immunomodulating agents |
PL2291080T3 (pl) | 2008-05-14 | 2015-12-31 | Scripps Research Inst | Nowe modulatory receptorów sfingozyno-1-fosforanu |
SG178042A1 (en) | 2009-07-16 | 2012-03-29 | Actelion Pharmaceuticals Ltd | Pyridin-4-yl derivatives |
-
2007
- 2007-09-06 CA CA2661105A patent/CA2661105C/en active Active
- 2007-09-06 DK DK07826287.0T patent/DK2069336T3/da active
- 2007-09-06 AU AU2007292993A patent/AU2007292993B2/en not_active Ceased
- 2007-09-06 NZ NZ576060A patent/NZ576060A/en not_active IP Right Cessation
- 2007-09-06 MY MYPI20090912A patent/MY149853A/en unknown
- 2007-09-06 TW TW096133280A patent/TWI392671B/zh active
- 2007-09-06 US US12/310,801 patent/US8580824B2/en active Active
- 2007-09-06 WO PCT/IB2007/053594 patent/WO2008029371A1/en active Application Filing
- 2007-09-06 PL PL07826287T patent/PL2069336T3/pl unknown
- 2007-09-06 AR ARP070103940A patent/AR062683A1/es active IP Right Grant
- 2007-09-06 RU RU2009112538/04A patent/RU2447071C2/ru active
- 2007-09-06 SI SI200731169T patent/SI2069336T1/sl unknown
- 2007-09-06 EP EP07826287A patent/EP2069336B1/en active Active
- 2007-09-06 ES ES07826287T patent/ES2400533T3/es active Active
- 2007-09-06 CL CL200702593A patent/CL2007002593A1/es unknown
- 2007-09-06 PT PT78262870T patent/PT2069336E/pt unknown
- 2007-09-06 MX MX2009002233A patent/MX2009002233A/es active IP Right Grant
- 2007-09-06 KR KR1020097006862A patent/KR101470659B1/ko active IP Right Grant
- 2007-09-06 BR BRPI0716171A patent/BRPI0716171B8/pt active IP Right Grant
- 2007-09-06 JP JP2009527264A patent/JP5253401B2/ja active Active
- 2007-09-06 CN CN200780033152XA patent/CN101511827B/zh active Active
-
2009
- 2009-03-04 IL IL197393A patent/IL197393A/en active IP Right Grant
- 2009-03-18 MA MA31729A patent/MA30718B1/fr unknown
- 2009-04-06 NO NO20091394A patent/NO342156B1/no unknown
-
2010
- 2010-02-11 HK HK10101596.4A patent/HK1133654A1/xx not_active IP Right Cessation
-
2013
- 2013-02-27 CY CY20131100186T patent/CY1113727T1/el unknown
- 2013-03-04 HR HRP20130181TT patent/HRP20130181T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0716171A2 (pt) | composto, composiÇço farmacÊutica e uso de um composto. | |
BRPI0815709A2 (pt) | composro, composição farmacêutica, e, uso de um composto. | |
BRPI0609802A2 (pt) | composto, composição farmacêutica e uso de um composto | |
BRPI0810696A2 (pt) | Composto, composição farmacêutica, e, uso de um composto | |
BRPI0919942A2 (pt) | Composto, composição farmacêutica, e, uso de um composto | |
BRPI0907562A2 (pt) | composto, composição farmacêutica, e, uso de um composto | |
BRPI0921375A2 (pt) | composto, composição farmacêutica, e, uso de um composto | |
BRPI0614205A2 (pt) | composto, composição farmacêutica, e, uso de composto | |
BRPI0614730A2 (pt) | composto, composição farmacêutica, e, uso de um composto | |
BRPI1007018A2 (pt) | composto, composição farmacêutica, e , uso de um composto. | |
BRPI0618904A2 (pt) | composto, composição farmacêutica, e, uso do composto | |
BRPI0810161A2 (pt) | Composto, preparação farmacêutica, composição farmacêutica, e, uso de um composto | |
BRPI1008906A2 (pt) | composto, composição farmacêutica, e, uso de um composto. | |
BRPI0921879A2 (pt) | composto, composição farmacêutica , e, uso de um composto | |
BRPI0810019A2 (pt) | Composto, composição farmacêutica, e, uso de um composto | |
BRPI0716698A2 (pt) | Composto, composição farmacêutica e uso de um composto | |
BRPI0814593A2 (pt) | Composto, composição farmacêutica que o contém e uso do composto. | |
BRPI0819696A2 (pt) | Compostos de derivados de 2-fenil-pirimidina, composição farmacêutica e uso de um composto | |
BRPI0821115A2 (pt) | Composto derivado de aminotriazol, medicamento, composição farmacêutica e uso do composto | |
BRPI0917579A2 (pt) | composto, composição farmacêutica, métodos, e, uso de um composto | |
BRPI0812942A2 (pt) | Composto, composição farmacêutica e uso de um composto | |
BRPI0908097A2 (pt) | uso de pelo menos um composto, peptídeo, e, formulação farmacêutica. | |
BRPI0917001A2 (pt) | composto, composição farmacêutica, e, uso de um composto ou uma composição farmacêutica | |
CL2007002377A1 (es) | Compuestos derivados de quinazolina; procedimiento de preparacion; composicion farmaceutica; y su uso como anticancerigeno. | |
BRPI0719398A2 (pt) | Composição farmacêutica. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25A | Requested transfer of rights approved |
Owner name: IDORSIA PHARMACEUTICALS LTD (CH) |
|
B25L | Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: publication cancelled |
Owner name: ACTELION PHARMACEUTICALS LTD (CH) |
|
B25C | Requirement related to requested transfer of rights |
Owner name: ACTELION PHARMACEUTICALS LTD (CH) |
|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B25A | Requested transfer of rights approved |
Owner name: IDORSIA PHARMACEUTICALS LTD (CH) |
|
B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 06/09/2007, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME MEDIDA CAUTELAR DE 07/04/2021 - ADI 5.529/DF |
|
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 06/09/2007 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |